trending Market Intelligence /marketintelligence/en/news-insights/trending/zV1ZRJMOLcI0-mcOI2u5Sw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Therapix lays off staff due to insufficient funds

Blog

Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021


Therapix lays off staff due to insufficient funds

Therapix Biosciences Ltd. has terminated the employment of all of its staff except interim CEO Ascher Shmulewitz due to a lack of sufficient funds.

CFO Oz Adler and Chief Technologies Officer Adi Zuloff-Shani will remain in their positions until March 30, 2020, as part of their 90-day notice period.

Therapix's remaining directors and officers will continue to seek fundraising opportunities, including the Israel-based medical cannabis company's planned combination with Heavenly Rx Ltd.

In November 2019, Therapix and Destiny Bioscience Global Corp. mutually agreed to discontinue talks on a proposed merger between the two companies.